You have full text access to this OnlineOpen article

CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome

  1. Y Taché1,*,
  2. V Martinez1,2,
  3. L Wang1,
  4. M Million1

Article first published online: 30 JAN 2009

DOI: 10.1038/sj.bjp.0705760

Issue

British Journal of Pharmacology

British Journal of Pharmacology

Volume 141, Issue 8, pages 1321–1330, April 2004

Additional Information

How to Cite

Taché, Y., Martinez, V., Wang, L. and Million, M. (2004), CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. British Journal of Pharmacology, 141: 1321–1330. doi: 10.1038/sj.bjp.0705760

Author Information

  1. 1

    CURE/Digestive Diseases Research Center, and Center for Neurovisceral Sciences and Woman's Health, West Los Angeles VA Medical Center, Division of Digestive Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, CA, U.S.A.

  2. 2

    Integrative Pharmacology-Gastrointestinal Biology, AstraZeneca R&D Mölndal, SE-431 83 Mölndal, Sweden

*CURE, Bldg 115, Room 117, VA Greater Los Angeles Health Care System, 1130 Wilshire Blvd, Los Angeles, CA 90073, U.S.A. E-mail: ytaché@ucla.edu

Publication History

  1. Issue published online: 30 JAN 2009
  2. Article first published online: 30 JAN 2009
  3. (Received February 11, 2004, Accepted February 25, 2004)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (264K)

References

  • ARBORELIUS, L., OWENS, M.J., PLOTSKY, P.M. & NEMEROFF, C.B. (1999). The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol., 160, 1–12.
  • ARDATI, A., GOETSCHY, V., GOTTOWICK, J., HENRIOT, S., VALDENAIRE, O., DEUSCHLE, U. & KILPATRICK, G.J. (1999). Human CRF2α and β splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay. Neuropharmacology, 38, 441–448.
  • BAKSHI, V.P. & KALIN, N.H. (2000). Corticotropin-releasing hormone and animal models of anxiety: gene–environment interactions. Biol. Psychiatry, 48, 1175–1198.
  • BALE, T.L., PICETTI, R., CONTARINO, A., KOOB, G.F., VALE, W.W. & LEE, K.F. (2002). Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. J. Neurosci., 22, 193–199.
  • BALE, T.L. & VALE, W.W. (2004). CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol., 44, 525–557.
  • BENNETT, E.J., TENNANT, C.C., PIESSE, C., BADCOCK, J. & KELLOW, J. (1998). Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut, 43, 256–261.
  • BITTENCOURT, J.C., VAUGHAN, J., ARIAS, C., RISSMAN, R.A., VALE, W.W. & SAWCHENKO, P.E. (1999). Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors. J. Comp. Neurol., 415, 285–312.
    Direct Link:
  • BLANK, T., NIJHOLT, I., GRAMMATOPOULOS, D.K., RANDEVA, H.S., HILLHOUSE, E.W. & SPIESS, J. (2003). Corticotropin-releasing factor receptors couple to multiple G-proteins to activate diverse intracellular signaling pathways in mouse hippocampus: role in neuronal excitability and associative learning. J. Neurosci., 23, 700–707.
  • BONAZ, B. & TACHÉ, Y. (1994). Water-avoidance stress-induced c-fos expression in the rat brain and stimulation of fecal output: role of corticotropin-releasing factor. Brain Res., 641, 21–28.
  • BRADESI, S., EUTAMENE, H., GARCIA-VILLAR, R., FIORAMONTI, J. & BUENO, L. (2002). Acute and chronic stress differently affect visceral sensitivity to rectal distension in female rats. Neurogastroenterol. Motil., 14, 75–82.
    Direct Link:
  • BRADY, L.S., GOLD, P.W., HERKENHAM, M., LYNN, A.B. & WHITFIELD JR, H.J. (1992). The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res., 572, 117–125.
  • CALOGERO, A.E., STERNBERG, E.M., BAGDY, G., SMITH, C., BERNARDINI, R., AKSENTIJEVICH, S., WILDER, R.L., GOLD, P.W. & CHROUSOS, G.P. (1992). Neurotransmitter-induced hypothalamic-pituitary–adrenal axis responsiveness is defective in inflammatory disease-susceptible Lewis rats: in vivo and in vitro studies suggesting globally defective hypothalamic secretion of corticotropin-releasing hormone. Neuroendocrinology, 55, 600–608.
  • CAMILLERI, M. (2001). Management of the irritable bowel syndrome. Gastroenterology, 120, 652–668.
  • CASTAGLIUOLO, I., LAMONT, J.T., QIU, B., FLEMING, S.M., BHASKAR, K.R., NIKULASSON, S.T., KORNETSKY, C. & POTHOULAKIS, C. (1996). Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells. Am. J. Physiol., 271, G884–G892.
  • CASTAGLIUOLO, I., WERSHIL, B.K., KARALIS, K., PASHA, A., NIKULASSON, S.T. & POTHOULAKIS, C. (1998). Colonic mucin release in response to immobilization stress is mast cell dependent. Am. J. Physiol, 274, G1094–G1100.
  • CHATZAKI, E., MURPHY, B.J., WANG, L., MILLION, M., OHNING, G.V., CROWE, P.D., PETROSKI, R., TACHÉ, Y. & GRIGORIADIS, D.E. (2004). CRF receptor type 1 and 2 expression and anatomical distribution in the rat colon. J. Neurochem., 88, 1–11.
    Direct Link:
  • COCHRANE, S.W., GIBSON, M.S., MYERS, D.A., SCHULKIN, J., RICE, K.C., GOLD, P.W. & GREENWOOD-VANMEERVELD, B. (2001). Role of corticotropin-releasing factor-1 (CRF1)-receptor mediated mechanisms in neural pathways modulating colonic hypersensitivity. Gastroenterology, 120 (Suppl 1), A-7.
  • COUTINHO, S.V., PLOTSKY, P.M., SABLAD, M., MILLER, J.C., ZHOU, H., BAYATI, A.I., MCROBERTS, J.A. & MAYER, E.A. (2002). Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat. Am. J. Physiol. Gastrointest. Liver Physiol., 282, G307–G316.
  • CRATTY, M.S., WARD, H.E., JOHNSON, E.A., AZZARO, A.J. & BIRKLE, D.L. (1995). Prenatal stress increases corticotropin-releasing factor (CRF) content and release in rat amygdala minces. Brain Res., 675, 297–302.
  • CREED, F. (1999). The relationship between psychosocial parameters and outcome in irritable bowel syndrome. Am. J. Med., 107, 74S–80S.
  • DAUTZENBERG, F.M. & HAUGER, R.L. (2002). The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol. Sci., 23, 71–77.
  • DE BELLIS, M.D., GOLD, P.W., GERACIOTI JR, T.D., LISTWAK, S.J. & KLING, M.A. (1993). Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am. J. Psychiatry, 150, 656–657.
  • DUNLOP, S.P., JENKINS, D., NEAL, K.R. & SPILLER, R.C. (2003). Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology, 125, 1651–1659.
  • ENCK, P. & HOLTMANN, G. (1992). Stress and gastrointestinal motility in animals: a review of the literature. J. Gastrointest. Motil., 1, 83–90.
  • FARGEAS, M.-J., FIORAMONTI, J. & BUÉNO, L. (1993). Central action of interleukin-1β on intestinal motility in rats: mediation by two mechanisms. Gastroenterology, 104, 377–383.
  • FORD, M.J., CAMILLERI, M., ZINSMEISTER, A.R. & HANSON, R.B. (1995). Psychosensory modulation of colonic sensation in the human transverse and sigmoid colon. Gastroenterology, 109, 1772–1780.
  • FRANCIS, D.D., CALDJI, C., CHAMPAGNE, F., PLOTSKY, P.M. & MEANEY, M.J. (1999). The role of corticotropin-releasing factor – norepinephrine systems in mediating the effects of early experience on the development of behavioral and endocrine responses to stress. Biol. Psychiatry, 46, 1153–1166.
  • FUKUDO, S., NOMURA, T. & HONGO, M. (1998). Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut, 42, 845–849.
  • FUNADA, M., HARA, C. & WADA, K. (2001). Involvement of corticotropin-releasing factor receptor subtype 1 in morphine withdrawal regulation of the brain noradrenergic system. Eur. J. Pharmacol., 430, 277–281.
  • GABRY, K.E., CHROUSOS, G.P., RICE, K.C., MOSTAFA, R.M., STERNBERG, E., NEGRAO, A.B., WEBSTER, E.L., MCCANN, S.M. & GOLD, P.W. (2002). Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs. Mol. Psychiatry, 7, 474–483 433.
  • GILLIGAN, P.J., ROBERTSON, D.W. & ZACZEK, R. (2000). Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J. Med. Chem., 43, 1641–1660.
  • GRAMMATOPOULOS, D.K. & CHROUSOS, G.P. (2002). Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol. Metab., 13, 436–444.
  • GUÉ, M., DEL RIO-LACHEZE, C., EUTAMENE, H., THEODOROU, V., FIORAMONTI, J. & BUENO, L. (1997). Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol. Motil., 9, 271–279.
    Direct Link:
  • GUÉ, M., JUNIEN, J.L. & BUÉNO, L. (1991). Conditioned emotional response in rats enhances colonic motility through the central release of corticotropin-releasing factor. Gastroenterology, 100, 964–970.
  • GULYAS, J., RIVIER, C., PERRIN, M., KOERBER, S.C., SUTTON, S., CORRIGAN, A., LAHRICHI, S.L., GRAIG, A.G., VALE, W. & RIVIER, J. (1995). Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc. Natl. Acad. Sci. U.S.A., 92, 10575–10579.
  • GUNTER, W.D., SHEPARD, J.D., FOREMAN, R.D., MYERS, D.A. & GREENWOOD-VAN MEERVELD, B. (2000). Evidence for visceral hypersensitivity in high-anxiety rats. Physiol. Behav., 69, 379–382.
  • GUTHRIE, E., CREED, F., DAWSON, D. & TOMENSON, B. (1991). A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology, 100, 450–457.
  • GUTMAN, D.A. & NEMEROFF, C.B. (2003). Persistent central nervous system effects of an adverse early environment: clinical and preclinical studies. Physiol. Behav., 79, 471–478.
  • HABIB, K.E., WELD, K.P., RICE, K.C., PUSHKAS, J., CHAMPOUX, M., LISTWAK, S., WEBSTER, E.L., ATKINSON, A.J., SCHULKIN, J., CONTOREGGI, C., CHROUSOS, G.P., MCCANN, S.M., SUOMI, S.J., HIGLEY, J.D. & GOLD, P.W. (2000). Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. U.S.A., 97, 6079–6084.
  • HARADA, S., IMAKI, T., NARUSE, M., CHIKADA, N., NAKAJIMA, K. & DEMURA, H. (1999). Urocortin mRNA is expressed in the enteric nervous system of the rat. Neurosci. Lett., 267, 125–128.
  • HAUGER, R.L., GRIGORIADIS, D.E., DALLMAN, M.F., PLOTSKY, P.M., VALE, W.W. & DAUTZENBERG, F.M. (2003). International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol. Rev., 55, 21–26.
  • HEINRICHS, S.C., DE SOUZA, E.B., SCHULTEIS, G., LAPSANSKY, J.L. & GRIGORIADIS, D.E. (2002). Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology, 27, 194–202.
  • HERNANDEZ, J.F., KORNREICH, W., RIVIER, C., MIRANDA, A., YAMAMOTO, G., ANDREWS, J., TACHÉ, Y., VALE, W. & RIVIER, J. (1993). Synthesis and relative potency of new constrained CRF antagonists. J. Med. Chem., 36, 2860–2867.
  • HIGELIN, J., PY-LANG, G., PATERNOSTER, C., ELLIS, G.J., PATEL, A. & DAUTZENBERG, F.M. (2001). 125I-Antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors. Neuropharmacology, 40, 114–122.
  • HOLSBOER, F. (1999). The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res., 33, 181–214.
  • IMAKI, T., KATSUMATA, H., MIYATA, M., NARUSE, M., IMAKI, J. & MINAMI, S. (2001). Expression of corticotropin-releasing hormone type 1 receptor in paraventricular nucleus after acute stress. Neuroendocrinology, 73, 293–301.
  • IMAKI, T., NARUSE, M., HARADA, S., CHIKADA, N., IMAKI, J., ONODERA, H., DEMURA, H. & VALE, W. (1996). Corticotropin-releasing factor up-regulates its own receptor mRNA in the paraventricular nucleus of the hypothalamus. Brain Res. Mol. Brain Res., 38, 166–170.
  • JEONG, K.H., JACOBSON, L., PACAK, K., WIDMAIER, E.P., GOLDSTEIN, D.S. & MAJZOUB, J.A. (2000). Impaired basal and restraint-induced epinephrine secretion in corticotropin-releasing hormone-deficient mice. Endocrinology, 141, 1142–1150.
  • JONES, J., BOORMAN, J., CANN, P., FORBES, A., GOMBORONE, J., HEATON, K., HUNGING, P., KUMAR, D., LIBBY, G., SPILLER, R., READ, N., SILK, D. & WHORWELL, P. (2000). British society of gastroenterology guidelines for the management of the irritable bowel syndrome. Gut, 47 (Suppl II), ii1–ii19.
  • KAMM, M.A. (1998). The role of psychosocial factors in functional gut disease. Eur. J. Surg. Suppl., 583 (Suppl), 37–40.
  • KECK, M.E. & HOLSBOER, F. (2001). Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides, 22, 835–844.
  • KEHNE, J. & DE LOMBAERT, S. (2002). Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Curr. Drug Target CNS Neurol. Disord., 1, 467–493.
  • KELLER, C., BRUELISAUER, A., LEMAIRE, M. & ENZ, A. (2002). Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. Drug Metab. Dispos., 30, 173–176.
  • KOSTICH, W.A., CHEN, A., SPERLE, K. & LARGENT, B.L. (1998). Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2ÿ receptor. Mol. Endocrinol., 12, 1077–1085.
  • KRESSE, A.E., MILLION, M., SAPERAS, E. & TACHÉ, Y. (2001). Colitis induces CRF expression in hypothalamic magnocellular neurons and blunts CRF gene response to stress in rats. Am. J. Physiol., 281, G1203–G1213.
  • LEMBO, T., PLOURDE, V., SHUI, Z., FULLERTON, S., MERTZ, H., TACHÉ, Y., SYTNIK, B., MUNAKATA, J. & MAYER, E. (1996). Effects of the corticotropin-releasing factor (CRF) on rectal afferent nerves in humans. Neurogastroenterol. Motil., 8, 9–18.
  • LENZ, H.J., BURLAGE, M., RAEDLER, A. & GRETEN, H. (1988b). Central nervous system effects of corticotropin-releasing factor on gastrointestinal transit in the rat. Gastroenterology, 94, 598–602.
  • LENZ, J.H. & DRUGE, G. (1990). Neurohumoral pathways mediating stress-induced inhibition of gastric acid secretion in rats. Gastroenterology, 98, 1490–1492.
  • LENZ, H.J., RAEDLER, A., GRETEN, H., VALE, W.W. & RIVIER, J.E. (1988a). Stress-induced gastrointestinal secretory and motor responses in rats are mediated by endogenous corticotropin-releasing factor. Gastroenterology, 95, 1510–1517.
  • LEWIS, K., LI, C., PERRIN, M.H., BLOUNT, A., KUNITAKE, K., DONALDSON, C., VAUGHAN, J., REYES, T.M., GULYAS, J., FISCHER, W., BILEZIKJIAN, L., RIVIER, J., SAWCHENKO, P.E. & VALE, W.W. (2001). Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A., 98, 7570–7575.
  • LI, C., VAUGHAN, J., SAWCHENKO, P.E. & VALE, W.W. (2002). Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J. Neurosci., 22, 991–1001.
  • LU, L., LIU, D., CENG, X. & MA, L. (2000). Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur. J. Neurosci., 12, 4398–4404.
  • LYDIARD, R.B. & FALSETTI, S.A. (1999). Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials. Am. J. Med., 107, 65S–73S.
  • MA, X.M. & LIGHTMAN, S.L. (1998). The arginine vasopressin and corticotrophin-releasing hormone gene transcription responses to varied frequencies of repeated stress in rats. J. Physiol. (Lond.), 510, 605–614.
    Direct Link:
  • MAILLOT, C., MILLION, M., WEI, J.Y., GAUTHIER, A. & TACHÉ, Y. (2000). Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats. Gastroenterology, 119, 1569–1579.
  • MAILLOT, C., WANG, L., MILLION, M. & TACHÉ, Y. (2003). Intraperitoneal corticotropin-releasing factor and urocortin induce Fos expression in brain and spinal autonomic nuclei and long lasting stimulation of colonic motility in rats. Brain Res., 974, 70–81.
  • MANCINELLI, R., AZZENA, G.B., DIANA, M., FORGIONE, A. & FRATTA, W. (1998). In vitro excitatory actions of corticotropin-releasing factor on rat colonic motility. J. Auton. Pharmacol., 18, 319–324.
    Direct Link:
  • MARTINEZ, V., RIVIER, J., WANG, L. & TACHÉ, Y. (1997). Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function. J. Pharmacol. Exp. Ther., 280, 754–760.
  • MARTINEZ, V. & TACHÉ, Y. (2001). Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats. Brain Res., 893, 29–35.
  • MARTINEZ, V., WANG, L., RIVIER, J., GRIGORIADIS, D. & TACHÉ, Y. (2004). Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice. J. Physiol., [Epub ahead of print] PMID: 14755002 PubMed.
  • MARTINEZ, V., WANG, L., RIVIER, J.E., VALE, W. & TACHÉ, Y. (2002). Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J. Pharmacol. Exp. Ther., 301, 611–617.
  • MAYER, E.A., NALIBOFF, B.D., CHANG, L. & COUTINHO, S.V. (2001). V. Stress and irritable bowel syndrome. Am. J. Physiol. Gastrointest.Liver Physiol., 280, G519–G524.
  • MCCARTHY, J.R., HEINRICHS, S.C. & GRIGORIADIS, D.E. (1999). Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr. Pharm. Des., 5, 289–315.
  • MIAMPAMBA, M., MAILLOT, C., MILLION, M. & TACHÉ, Y. (2002). Peripheral CRF activates myenteric neurons in the proximal colon through CRF1 receptor in conscious rats. Am. J. Physiol., 282, G857–G865.
  • MILLION, M., GRIGORIADIS, D.E., SULLIVAN, S., CROWE, P.D., MCROBERTS, J.E., ZHOU, C.Y., SAUNDERS, P.R., MAILLOT, C., MAYER, A.E. & TACHÉ, Y. (2003). A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats. Brain Res., 985, 32–42.
  • MILLION, M., MAILLOT, C., SAUNDERS, P.R., RIVIER, J., VALE, W. & TACHÉ, Y. (2002). Human urocortin II, a new CRF-related peptide, displays selective CRF2-mediated action on gastric transit in rats. Am. J. Physiol., 282, G34–G40.
  • MILLION, M., WANG, L., MARTINEZ, V. & TACHÉ, Y. (2000). Differential Fos expression in the paraventricular nucleus of the hypothalamus, sacral parasympathetic nucleus and colonic motor response to water avoidance stress in Fischer and Lewis rats. Brain Res., 877, 345–353.
  • MIRANDA, A., LAHRICHI, S.L., GULYAS, J., KOERBER, S.C., CRAIG, A.G., CORRIGAN, A., RIVIER, C., VALE, W. & RIVIER, J. (1997). Constrained corticotropin-releasing factor antagonists with i-(i + 3) Glu–Lys bridges. J. Med. Chem., 40, 3651–3658.
  • MIYATA, K., ITO, H. & FUKUDO, S. (1998). Involvement of the 5-HT3 receptor in CRH-induce defecation in rats. Am. J. Physiol., 274, G827–G831.
  • MÖNNIKES, H., HEYMANN-MONNIKES, I. & TACHÉ, Y. (1992a). CRF in the paraventricular nucleus of the hypothalamus induces dose-related behavioral profile in rats. Brain Res., 574, 70–76.
  • MÖNNIKES, H., RAYBOULD, H.E., SCHMIDT, B. & TACHÉ, Y. (1993b). CRF in the paraventricular nucleus of the hypothalamus stimulates colonic motor activity in fasted rats. Peptides, 14, 743–747.
  • MÖNNIKES, H., SCHMIDT, B.G., RAYBOULD, H.E. & TACHÉ, Y. (1992b). CRF in the paraventricular nucleus mediates gastric and colonic motor response to restraint stress. Am. J. Physiol., 262, G137–G143.
  • MÖNNIKES, H., SCHMIDT, B.G. & TACHÉ, Y. (1993a). Psychological stress-induced accelerated colonic transit in rats involves hypothalamic corticotropin-releasing factor. Gastroenterology, 104, 716–723.
  • MÖNNIKES, H., SCHMIDT, B.G., TEBBE, J., BAUER, C. & TACHÉ, Y. (1994). Microinfusion of corticotropin releasing factor into the locus coeruleus/subcoeruleus stimulates colonic motor function in rats. Brain Res., 644, 101–108.
  • MORIN, S.M., LING, N., LIU, X.J., KAHL, S.D. & GEHLERT, D.R. (1999). Differential distribution of urocortin- and corticotropin-releasing factor-like immunoreactivities in the rat brain. Neuroscience, 92, 281–291.
  • MORROW, N.S. & GARRICK, T. (1997). Effects of intermittent tail shock or water avoidance on proximal colonic motor contractility in rats. Physiol. Behav., 62, 233–239.
  • MURAMATSU, Y., FUKUSHIMA, K., IINO, K., TOTSUNE, K., TAKAHASHI, K., SUZUKI, T., HIRASAWA, G., TAKEYAMA, J., ITO, M., NOSE, M., TASHIRO, A., HONGO, M., OKI, Y., NAGURA, H. & SASANO, H. (2000). Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa. Peptides, 21, 1799–1809.
  • NORTH, C.S., ALPERS, D.H., THOMPSON, S.J. & SPITZNAGEL, E.L. (1996). Gastrointestinal symptoms and psychiatric disorders in the general population: findings from NIMH epidemiologic catchement area project. Dig. Dis. Sci., 41, 633–640.
  • OKANO, S., NAGAYA, H., IKEURA, Y., NATSUGARI, H. & INATOMI, N. (2001). Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo. J. Pharmacol. Exp. Ther., 298, 559–564.
  • PERRIN, M.H. & VALE, W.W. (1999). Corticotropin releasing factor receptors and their ligand family. Ann. NY Acad. Sci., 885, 312–328.
    Direct Link:
  • PISARCHIK, A. & SLOMINSKI, A. (2002). Corticotropin releasing factor receptor type 1: molecular cloning and investigation of alternative splicing in the hamster skin. J. Invest. Dermatol., 118, 1065–1072.
  • RAO, S.S., HATFIELD, R.A., SULS, J.M. & CHAMBERLAIN, M.J. (1998). Psychological and physical stress induce differential effects on human colonic motility. Am. J. Gastroenterol., 93, 985–990.
    Direct Link:
  • REYES, T.M., LEWIS, K., PERRIN, M.H., KUNITAKE, K.S., VAUGHAN, J., ARIAS, C.A., HOGENESCH, J.B., GULYAS, J., RIVIER, J., VALE, W.W. & SAWCHENKO, P.E. (2001). Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A., 98, 2843–2848.
  • RIVEST, S., LAFLAMME, N. & NAPPI, R.E. (1995). Immune challenge and immobilization stress induce transcription of the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus. J. Neurosci., 15, 2680–2695.
  • RIVIER, J., GULYAS, J., KIRBY, D., LOW, W., PERRIN, M.H., KUNITAKE, K., DIGRUCCIO, M., VAUGHAN, J., REUBI, J.C., WASER, B., KOERBER, S.C., MARTINEZ, V., WANG, L., TACHÉ, Y. & VALE, W. (2002). Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J. Med. Chem., 45, 4737–4747.
  • RIVIER, J., RIVIER, C. & VALE, W. (1984). Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science, 224, 889–891.
  • RIVIER, J.E., KIRBY, D.A., LAHRICHI, S.L., CORRIGAN, A., VALE, W.W. & RIVIER, C.L. (1999). Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat. J. Med. Chem., 42, 3175–3182.
  • RUHMANN, A., BONK, I., LIN, C.R., ROSENFELD, M.G. & SPIESS, J. (1998). Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2β-selective antisauvagine-30. Proc. Natl. Acad. Sci. U.S.A., 95, 15264–15269.
  • SAGAMI, Y., SHIMADA, Y., TAYAMA, J., NOMURA, T., SATAKE, M., ENDO, Y., SHOJI, T., KARAHASHI, K., HONGO, M. & FUKUDO, S. (2004). Effect of a corticotropin-releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut, in press.
  • SANTOS, J., SAUNDERS, P.R., HANSSEN, N.P.M., YANG, P.C., YATES, D., GROOT, J.A. & PERDUE, M.H. (1999). Corticotropin-releasing hormone mimics stress-induced rat colonic epithelial pathophysiology in the rat. Am. J. Physiol., 277, G391–G399.
  • SAUNDERS, P.R., MAILLOT, C., MILLION, M. & TACHÉ, Y. (2002a). Peripheral corticotropin-releasing factor induces diarrhea in rats: role of CRF1 receptor in fecal watery excretion. Eur. J. Pharmacol., 435, 231–235.
  • SAUNDERS, P.R., SANTOS, J., HANSSEN, N.P., YATES, D., GROOT, J.A. & PERDUE, M.H. (2002b). Physical and psychological stress in rats enhances colonic epithelial permeability via peripheral CRH. Dig. Dis. Sci., 47, 208–215.
  • SCHULZ, D.W., MANSBACH, R.S., SPROUSE, J., BRASELTON, J.P., COLLINS, J., CORMAN, M., DUNAISKIS, A., FARACI, S., SCHMIDT, A.W., SEEGER, T., SEYMOUR, P., TINGLEY III, F.D., WINSTON, E.N., CHEN, Y.L. & HEYM, J. (1996). CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. U.S.A., 93, 10477–10482.
  • SOLMAZ, M., KAVUK, J & SAYAR, K. (2003). Psychological factors in the irritable bowel syndrome. Eur. J. Med. Res., 8, 549–556.
  • TACHÉ, Y. (2002). The parasympathetic nervous system in the pathophysiology of the gastrointestinal tract. In Handbook of Autonomic Nervous System in Health and Disease, eds. Bolis, C.L., Licinio, J., & Govoni, S. pp. 463–503. New York: Dekker, Inc.
  • TACHÉ, Y., MARTINEZ, V., MILLION, M. & WANG, L. (2001). Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am. J. Physiol, 280, G173–G177.
  • TACHÉ, Y. & PERDUE, M.H. (2004). Role of peripheral CRF signaling pathways in stress-related alterations of gut motility and mucosal function. Neurogastroenterol. Mot., 16 (Suppl 1), 1–6.
  • TALLEY, N.J. & SPILLER, R. (2002). Irritable bowel syndrome: a little understood organic bowel disease Lancet, 360, 555–564.
  • TURNBULL, A.V. & RIVIER, C.L. (1999). Regulation of the hypothalamic-pituitary–adrenal axis by cytokines: actions and mechanisms of action. Physiol. Rev., 79, 1–71.
  • VALE, W., SPIESS, J., RIVIER, C. & RIVIER, J. (1981). Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science, 213, 1394–1397.
  • VAUGHAN, J., DONALDSON, C., BITTENCOURT, J., PERRIN, M.H., LEWIS, K., SUTTON, S., CHAN, R., TURNBULL, A.V., LOVEJOY, D., RIVIER, C., RIVIER, J., SAWCHENKO, P.E. & VALE, W. (1995). Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature, 378, 287–292.
  • VIZZARD, M.A., BRISSON, M. & DE GROAT, W.C. (2000). Transneuronal labeling of neurons in the adult rat central nervous system following inoculation of pseudorabies virus into the colon. Cell Tissue Res., 299, 9–26.
  • WEBSTER, E.L., LEWIS, D.B., TORPY, D.J., ZACHMAN, E.K., RICE, K.C. & CHROUSOS, G.P. (1996). In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology, 137, 5747–5750.
  • WEISS, J.M., STOUT, J.C., AARON, M.F., QUAN, N., OWENS, M.J., BUTLER, P.D. & NEMEROFF, C.B. (1994). Depression and anxiety: role of the locus coeruleus and corticotropin-releasing factor. Brain Res. Bull., 35, 561–572.
  • WENINGER, S.C., DUNN, A.J., MUGLIA, L.J., DIKKES, P., MICZEK, K.A., SWIERGIEL, A.H., BERRIDGE, C.W. & MAJZOUB, J.A. (1999). Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc. Natl. Acad. Sci. U.S.A., 96, 8283–8288.
  • WILLIAMS, C.L., PETERSON, J.M., VILLAR, R.G. & BURKS, T.F. (1987). Corticotropin-releasing factor directly mediates colonic responses to stress. Am. J. Physiol., 253, G582–G586.
  • YAMAMOTO, O., NIIDA, H., TAJIMA, K., SHIROUCHI, Y., MASUI, Y., UEDA, F., KISE, M. & KIMURA, K. (1998). Inhibition of stress-stimulated colonic propulsion by alpha 2-adrenoceptor antagonists in rats. Neurogastroenterol. Motil., 10, 523–532.
    Direct Link:
  • ZOBEL, A.W., NICKEL, T., KUNZEL, H.E., ACKL, N., SONNTAG, A., ISING, M. & HOLSBOER, F. (2000). Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatry Res., 34, 171–181.
  • ZORRILA, E.P., TACHÉ, Y. & KOOB, G.F. (2003). Nibbling at CRF receptor control of feeding and gastrocolonic motility. Trends Pharmacol. Sci., 24, 421–427.
View Full Article (HTML) Get PDF (264K)